Brett Sandercock Net Worth

The estimated Net Worth of Brett Sandercock is at least $75.2 Million dollars as of 9 September 2024. Mr. Sandercock owns over 1,000 units of Resmed stock worth over $24,485,691 and over the last 19 years he sold RMD stock worth over $47,845,651. In addition, he makes $2,907,650 as Chief Financial Officer at Resmed.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Sandercock RMD stock SEC Form 4 insiders trading

Brett has made over 117 trades of the Resmed stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of RMD stock worth $246,420 on 9 September 2024.

The largest trade he's ever made was exercising 100,000 units of Resmed stock on 13 February 2015 worth over $1,552,000. On average, Brett trades about 6,210 units every 45 days since 2005. As of 9 September 2024 he still owns at least 96,812 units of Resmed stock.

You can see the complete history of Mr. Sandercock stock trades at the bottom of the page.

Brett Sandercock biography

Brett A. Sandercock CPA serves as Chief Financial Officer of the Company. Mr. Sandercock was manager of Financial Accounting and Group Reporting at Norton Abrasives, a division of Saint-Gobain, a French multinational corporation. He also held finance and accounting roles at Health Care of Australia, a large private hospital operator. he worked at Pricewaterhouse Coopers in Sydney, specializing in audits of clients across distribution and manufacturing, financial services, technology, and other industries. From June 2019 to present, he has served as non-executive chairman of the board of directors of Osteopore Limited (ASX:OSX), an Australian and Singapore based medical technology company, commercializing products used for the regeneration of bone across a range of therapeutic areas. Mr. Sandercock holds a bachelor’s in economics from Macquarie University in Sydney, and is a Certified Chartered Accountant.

What is the salary of Brett Sandercock?

As the Chief Financial Officer of Resmed, the total compensation of Brett Sandercock at Resmed is $2,907,650. There are 4 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.

How old is Brett Sandercock?

Brett Sandercock is 53, he's been the Chief Financial Officer of Resmed since 2006. There are 16 older and 5 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.

What's Brett Sandercock's mailing address?

Brett's mailing address filed with the SEC is RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123.

Insiders trading at Resmed

Over the last 22 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, and David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.

What does Resmed do?

at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

Complete history of Mr. Sandercock stock trades at Resmed

Resmed executives and stock owners

Resmed executives and other stock owners filed with the SEC include:

• Michael Farrell,
  Chief Executive Officer, Director
• Robert Douglas,
  President, Chief Operating Officer
• Jim Hollingshead,
  President – sleep and respiratory care business
• Rajwant Sodhi,
  President – Software as a Service Business (SaaS)
• Brett Sandercock,
  Chief Financial Officer
• Michael J. Farrell BE, SM, MBA,
  CEO & Director
• David Pendarvis,
  Chief Administrative Officer, Global General Counsel, Secretary
• Michael J. Farrell BE, MBA, SM,
  CEO & Director
• Robert A. Douglas,
  Pres & COO
• Dr. James R. Hollingshead Ph.D.,
  Pres of Sleep & Respiratory Care Bus.
• Brett A. Sandercock,
  Chief Financial Officer
• Peter Farrell,
  Non-Executive Chairman of the Board
• Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD,
  Founder & Non-Exec. Chairman
• Dr. Peter C. Farrell A.M., B.E., Ph.D., BE (Hons), ScD, AM,
  Founder & Non-Exec. Chairman
• Ronald Taylor,
  Lead Independent Director
• Carol Burt,
  Independent Director
• Richard Sulpizio,
  Independent Director
• Harjit Gill,
  Independent Director
• Jan De Witte,
  Independent Director
• Karen Drexler,
  Independent Director
• Justin Leong,
  President – Asia and Latin America
• Urvashi Tyagi,
  Chief Technology Officer
• Nupur Bhushan,
  Chief People Officer
• David B. Pendarvis,
  Chief Admin. Officer, Global Gen. Counsel & Corp. Sec.
• Amy Wakeham,
  VP of Investor Relations & Corp. Communications
• Constance C. Bienfait,
  Director of Investor Relations
• Kaushik Ghoshal,
  Pres of SaaS Bus. & CTO
• John P Wareham,
  Director
• Christopher G Roberts,
  Director
• Donald Darkin,
  Sr. Vice President, Pat Inter
• Gary W Pace,
  Director
• Anne Reiser,
  President - ResMed Europe
• Richard Mc Hale,
  President, RC Business
• Inc Resmed,
  Director
• James Hollingshead,
  President, Sleep Business
• Kieran Gallahue,
  President, Global
• Paul Eisen,
  Vice President, Europe & Asia
• Donagh Mccarthy,
  Director
• Adrian M Smith,
  CFO
• Klaus H Shindhelm,
  Sr. Vice President, Operations
• Keith Serzen,
  Chief Operating Officer
• Louis A Simpson,
  Director
• Christopher Bartlett,
  Director
• Walter Flicker,
  VP and Asst. Corp. Secretary
• Lasse Beijer,
  COO-Europe
• Stein Jacobsen,
  COO, Europe
• Michael A Quinn,
  Director
• Kaushik Ghoshal,
  President, SaaS Business
• Lucile Blaise,
  President, Sleep & RC Business
• John Hernandez,
  Director
• Desney Tan,
  Director
• Michael J Rider,
  Global General Counsel
• Christopher Del Orefice,
  Director